Kala Bio and Virotek sign distribution partnership for ophthalmology genetic testing

ARLINGTON, Mass., Sept. 01, 2026 /CourierPR/ -- Kala Bio and Virotek Inc. have signed a letter of intent to establish an exclusive U.S. distribution partnership for Virotek's ophthalmology genetic testing and screening program. This collaboration aims to leverage Kala Bio's extensive market presence and Virotek's advanced genomics technologies to expand access to precision healthcare solutions in the U.S.

Under the agreement, Kala Bio will market, promote, and distribute Virotek's ophthalmology genetic testing and screening program to eye care practices, telehealth platforms, and other relevant channels across the United States. Virotek, a CLIA-registered precision health and clinical genomics company, will continue to operate its laboratory infrastructure and handle specimen processing, kit fulfillment, and clinical reporting. The partnership also opens the possibility for future expansion into additional clinical areas, including oncology and preventive health testing, as well as telehealth and white-label distribution channels.

Avi Minkowitz, CEO of Kala Bio, expressed optimism about the partnership: "This is an accretive step for Kala Bio, aligning with our mission to provide clinically validated diagnostics to the clinicians and patients who need them most. Virotek's program perfectly fits within our commercial network and therapeutic focus."

Dr. Saeid Babaei, CEO of Virotek, added, "Kala's commercial reach provides our ophthalmology program with a fast, credible path to patients across the U.S., and we are excited to collaborate with a partner who understands this space well."

Kala Bio, based in the U.S., is a clinical-stage biopharmaceutical company focused on advancing AI infrastructure for the biotechnology industry. The company's pipeline includes a mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates. Virotek, headquartered in Wyoming, specializes in precision health and clinical genomics, offering a comprehensive platform for preventive risk assessment, early cancer detection, and personalized treatment guidance.

The partnership remains contingent on the negotiation and execution of definitive agreements, as well as other customary conditions, including regulatory and Nasdaq approvals. Kala and Virotek are targeting the execution of definitive agreements within 30 days of signing the letter of intent.

Both companies are optimistic about the potential benefits of this collaboration, with Kala Bio's Minkowitz stating, "We look forward to moving quickly toward a definitive agreement to realize the full potential of this partnership."